SEC Form 4 · accession 0001179110-16-027530
ACCELERON PHARMA INC · XLRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Knopf
Officer — CEO and President · Director
Period of report
Jul 7, 2016
Accepted (ET)
Jul 7, 2016 · 4:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001280600
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 7, 2016 | M | 95,000 | $1.80 | A | 214,084 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $1.80 | Jul 7, 2016 | M | 95,000 | D | — | Jan 31, 2017 | Common Stock | 95,000 | 0 | D |
Explanation of responses
- F1The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant.